Compare AIOT & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIOT | KROS |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 665.1M | 655.9M |
| IPO Year | N/A | 2020 |
| Metric | AIOT | KROS |
|---|---|---|
| Price | $5.61 | $19.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 12 |
| Target Price | $10.50 | ★ $22.20 |
| AVG Volume (30 Days) | ★ 1.1M | 538.6K |
| Earning Date | 02-09-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.57 |
| Revenue | ★ $425,867,000.00 | $246,718,000.00 |
| Revenue This Year | $23.71 | $6,924.79 |
| Revenue Next Year | $9.22 | N/A |
| P/E Ratio | ★ N/A | $11.80 |
| Revenue Growth | 92.93 | ★ 37798.31 |
| 52 Week Low | $3.70 | $9.12 |
| 52 Week High | $8.71 | $22.55 |
| Indicator | AIOT | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 60.78 | 49.54 |
| Support Level | $5.38 | $17.51 |
| Resistance Level | $5.63 | $18.85 |
| Average True Range (ATR) | 0.19 | 0.74 |
| MACD | 0.01 | -0.36 |
| Stochastic Oscillator | 87.96 | 43.30 |
PowerFleet Inc is engaged in Internet-of-Things (IoT) solutions providing valuable business intelligence for managing high-value enterprise assets that improve operational efficiencies. It provide critical information that powers unified operations throughout organizations. It is solving the challenge of inefficient data collection, real-time visibility, and analysis that leads to transformative business operations. Its SaaS cloud-based applications take data from IoT devices and ecosystem of third-party and partner applications to present actionable information for customer.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.